Sana Biotechnology, Inc.

Sana Biotechnology, Inc. (SANA) priced its initial public offering on Feb 5, 2021 at $25.00 per share, raising $587.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $4.6B. BofA Securities was lead-left underwriter, joined by Morgan Stanley, Goldman Sachs and J.P. Morgan. Latham & Watkins advised the company and Cooley advised the underwriters.

Sana Biotechnology, Inc. is developing in vivo and ex vivo cell engineering platforms for therapies across areas with unmet need, including oncology, diabetes and central nervous system disease. Its stated long-term aims include controlling or modifying any gene in the body and replacing damaged or missing cells.

Status

IPO

Ticker

SANA

Exchange

Nasdaq Global Select

Priced

Feb 5, 2021

IPO price

$25.00

Raised

$587.5M

Market cap at IPO price

$4.6B

First filed

Jan 13, 2021

Underwriters

BofA Securities, Morgan Stanley, Goldman Sachs and J.P. Morgan

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

WA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.